Clinical trials in Milan – page 89

2 391 clinical trials in Milan, Italy across 15 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Milan at a glance

2 391

clinical trials

Research sites15

Quick filters

2 391 trials in Milan

Open in trial search

Thrombotic thrombocytopenic purpura+1

Not yet recruiting

A study to evaluate the safety and effectiveness of urokinase, catalytic domain, fused with a single-chain antibody against von Willebrand factor in patients with immune-mediated thrombotic thrombocytopenic purpura.

InvestigationalNo placebo

A study to evaluate the safety and effectiveness of urokinase, catalytic domain, fused with a single-chain antibody against von Willebrand factor in patients with immune-mediated thrombotic thrombocytopenic purpura.

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:UROKINASE, CATALYTIC DOMAIN, FUSED WITH A SINGLE-CHAIN ANTIBODY AGAINST VON WILLEBRAND FACTOR
Sponsor:TargED Biopharmaceuticals B.V.

Contact Research Centre

Congenital growth hormone deficiency

Not yet recruiting

Study of the effects of Ibutamoren Mesilate in prepubertal children with growth hormone deficiency

Investigational

Study of the effects of Ibutamoren Mesilate in prepubertal children with growth hormone deficiency

Investigational

Italy

Participants:0–17 years
Substances:Ibutamoren Mesilate
Sponsor:Lumos Pharma Inc.

Contact Research Centre

Osteoporosis postmenopausal

Not yet recruiting

Comparing the effect of romosozumab and denosumab on coronary artery damage in women with postmenopausal osteoporosis

Registered drugNo placebo

Comparing the effect of romosozumab and denosumab on coronary artery damage in women with postmenopausal osteoporosis

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Denosumab
Sponsor:Ospedale Galeazzi S.p.A.

Contact Research Centre

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:ADMILPARANT
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Idiopathic pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

Investigational

A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:ADMILPARANT
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Glioblastoma

Not yet recruiting

Phase 3 Randomized Study of Niraparib Tosilate Monohydrate vs. Temozolomide in Newly Diagnosed MGMT Unmethylated Glioblastoma

Registered drugNo placebo

Phase 3 Randomized Study of Niraparib Tosilate Monohydrate vs. Temozolomide in Newly Diagnosed MGMT Unmethylated Glioblastoma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Temozolomide
Sponsor:Neurotrials LLC

Contact Research Centre

Pancreatic carcinoma metastatic+1

Not yet recruiting

A Study of Ponsegromab Combined with Chemotherapy for Adults with Pancreatic Cancer that has Spread and Caused Weight Loss

Registered drug

A Study of Ponsegromab Combined with Chemotherapy for Adults with Pancreatic Cancer that has Spread and Caused Weight Loss

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Ponsegromab
Sponsor:Pfizer Inc.

Contact Research Centre

Lung cancer metastatic

Not yet recruiting

Study of Drug Combination with Pembrolizumab Guided by Blood Biomarkers for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo

Study of Drug Combination with Pembrolizumab Guided by Blood Biomarkers for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Contact Research Centre

Plasma cell myeloma refractory

Not yet recruiting

A Study of Linvoseltamab Alone and Linvoseltamab with Carfilzomib Compared to Standard Treatment in Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

A Study of Linvoseltamab Alone and Linvoseltamab with Carfilzomib Compared to Standard Treatment in Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Aciclovir
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Endocrine ophthalmopathy

Not yet recruiting

A study testing teprotumumab compared to placebo in adult patients with moderate-to-severe active thyroid eye disease

Investigational

A study testing teprotumumab compared to placebo in adult patients with moderate-to-severe active thyroid eye disease

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Teprotumumab
Sponsor:Horizon Therapeutics USA Inc.

Contact Research Centre

Inflammation

Not yet recruiting

Testing acetylsalicylic acid and ketorolac to reduce complications after cancer surgery in patients with high inflammation levels

Registered drugNo placebo

Testing acetylsalicylic acid and ketorolac to reduce complications after cancer surgery in patients with high inflammation levels

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Acetylsalicylic Acid
Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Contact Research Centre

Uveal melanoma

Not yet recruiting

A study comparing RP2 with nivolumab versus ipilimumab with nivolumab in adults with metastatic uveal melanoma not previously treated with immune checkpoint inhibitors

Registered drugNo placebo

A study comparing RP2 with nivolumab versus ipilimumab with nivolumab in adults with metastatic uveal melanoma not previously treated with immune checkpoint inhibitors

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Ipilimumab
Sponsor:Replimune Group Inc.

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Milan

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on colorectal cancer, breast cancer prevention, and advanced solid tumors. Studies include evaluation of novel therapeutic approaches and diagnostic methods.

Metastatic Colorectal Cancer Treatment
Breast Cancer Prevention Strategies
Advanced Solid Malignancies

Research emphasizes personalized treatment approaches and preventive interventions for high-risk patients.

02 Neurological Disorders

Research initiatives targeting neurodegenerative conditions and chronic headache disorders, with studies examining innovative therapeutic approaches.

Frontotemporal Dementia
Parkinson's Disease
Migraine Treatment

Focus on developing targeted therapies and understanding disease mechanisms.

03 Immunology and Infectious Diseases

Studies investigating treatments for autoimmune conditions and infectious diseases, including preventive approaches and therapeutic interventions.

Immune Thrombocytopenia
RSV Prevention
HIV Prevention

Emphasis on developing novel preventive strategies and therapeutic solutions.

Back to Italy All countries